10-Q quarterly report · filed Oct 30, 2026

LIGAND PHARMACEUTICALS INC (LGND) Q3 2026 10-Q Quarterly Report

Short answer

LIGAND PHARMACEUTICALS INC (LGND) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $79M (down 31.8% year over year) with net income of −$28M.

Q3 2026 key financials · XBRL

Revenue
$79M
−31.8% YoY · +23.6% QoQ
Net income
−$28M
−124.3% YoY · −158.7% QoQ
Operating margin
-19.4%
EPS (diluted)
−$1.32
−122.4% YoY · −157.4% QoQ

Source: XBRL data from the LIGAND PHARMACEUTICALS INC (LGND) Q3 2026 10-Q on SEC EDGAR. USD.

LIGAND PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue and income $78.7M, down $36.7M or 32% YoY from $115.5M
  • Net loss $28.5M vs net income $117.3M; operating costs 120% of revenue vs 52% YoY
  • Best performer royalties $70.3M, up 51%; Filspari royalty revenue $16.8M vs $9.1M
  • Cash, equivalents and short-term investments $447.4M vs $733.5M at December 31, 2025; operating cash flow $45.1M YTD
  • XOMA acquisition and investments drove liquidity decline; management expects resources sufficient for at least twelve months

Risk Factors

  • New acquisition risk triggered by July 14, 2026 XOMA Acquisition: integration may disrupt systems, personnel retention and royalty portfolio administration
  • Royalty revenue risk: counterparties may buy out obligations below future royalties’ net present value
  • Debt liquidity risk: 2030 Notes and 2031 Notes may require cash repurchases after specified events
  • Financing risk: insufficient operating cash flow could force asset sales, debt restructuring or highly dilutive financing
  • Litigation risk: potential XOMA Acquisition litigation disclosed, though not currently expected to be material

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other LIGAND PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.